NewLimit has raised a $130M Series B led by Kleiner Perkins alongside NFDG, @khoslaventures.bsky.social, Human Capital and returning investors Dimension & Founders Fund We're grateful for their boldness in joining us on our journey to extend human healthspan blog.newlimit.com/p/newlimit-r...

each year @newlimitbio.bsky.social, we share an update on our progress with the public this week, we revealed the early results from our programs in metabolism & immunology. we’re starting to see the first hints of reprogramming medicines on the horizon. watch here: m.youtube.com/watch?v=HR0-...

2024 @newlimitbio.bsky.social: - 10X Engine throughput - Discovered TF sets that reprogram cell age & preserve type - Restored youthful function in a disease model with drug-like reprogramming we demonstrated that reprogramming medicines are possible 2025: we start to develop them bit.ly/4h7rrD3

early autumn @newlimitbio.bsky.social: - 0 → 70 TF sets tested in human hepatocytes via a chimeric liver system - +2779 TF sets tested in T cells - +51 sets that reverse phenotypic age in T cells - 5 → 7 functional assays for hepatocyte age - 0 → 80% efficiency LNP-mRNA delivery bit.ly/4g0NKJV

late summer @newlimit - world's largest partial reprogramming screen (again) - 3x'd speed of sequencing turn-around - 5x'd reprog factor library size - built our first integrated reprog corpus for model training - team += 3 blog.newlimit.com/p/july-augus...